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Abstract 
Aim 
Joint Hypermobility Syndrome (JHS) is an inherited disorder of the connective tissue and can lead to 
widespread pain, joint instability and fatigue. In order to understand where patients with 
musculoskeletal symptoms and JHS present to secondary care we have established the prevalence of 
JHS within the pain management service, a general rheumatology clinic and an orthopaedic clinic of a 
single general hospital. 
Method 
A total of 138 patients attending the pain management service, a general rheumatology clinic and an 
orthopaedic clinic were surveyed for Joint Hypermobility Syndrome as part of their usual care using the 
Brighton criteria.  
Results 
The pain management and general rheumatology clinics both demonstrated a similar prevalence of 
39.1% and 37.0% respectively. The orthopaedics clinic demonstrated a much lower prevalence of 10.9%.   
Conclusion 
There were a higher number of people with JHS presenting to the pain management and general 
rheumatology clinics than the orthopaedic clinic. This reflects an appropriate pathway for this multiple 
joint pathology. The difficulty in classifying people with JHS is discussed as these figures may reflect an 
over classification of the condition.  
 
 
 
Introduction 
Joint Hypermobility Syndrome (JHS) is an inherited disorder of the connective tissue. The common 
feature is pain but as this is a disorder of collagen that occurs throughout the body it has features such 
as varicose veins, uterine or rectal prolapse, hernias(1), cardiovascular, pulmonary, gastrointestinal and 
gynaecological problems (2). More surprising characteristics such as disturbances to pain perception 
(3;4), anxiety (5), fatigue (6) and osteoporosis (7) are also seen. Regarding the physical features, the 
spectrum is broad, with some people suffering very few symptoms and others with chronic long-
standing joint pain, subluxations/dislocations, sprains, clumsiness and problems with activities ranging 
from sport to even simple writing tasks (8). 
Classifying JHS is difficult because, unlike other hypermobility syndromes there are no specific genetic 
tests that define the syndrome (2). Further, there is some confusion as JHS may be the same condition 
as Ehlers Danlos Syndrome – Hypermobility Type (EDS-HT) formerly called Ehlers Danlos Syndrome – 
Type III (9). To add to the confusion, JHS has an asymptomatic counterpart that has been termed 
Generalised Joint Hypermobility (GJH). Classification is therefore important. The Beighton score is often 
used to assess the degree of general joint flexibility, measuring specific areas of joint hypermobility. It is 
recognised as a somewhat crude scale but was originally designed as a quick tool to identify 
hypermobility in population studies (10;11). There are some disagreements as to the cut off score, 
which varies with age (12-15), but commonly a score of 4 or more out of 9 joints represents GJH in 
adults (16). Joint Hypermobility Syndrome is further classified using either the Brighton Criteria (17) or 
Villefranche Classification (Table 1). These classifications have the Beighton score embedded and also 
determine signs and symptoms commonly recognised as part of the syndrome. The Brighton criteria was 
originally designed in recognition of the extra articular features of joint hypermobility syndrome 
(Grahame et al., 2000), however its validity has been questioned (11). The Villefranche Classification 
focuses upon features of inheritance and was developed to identify EDS-HT; the Brighton Criteria 
focuses upon signs and symptoms and is used to classify JHS. The Brighton criterion has two major and 
eight minor criteria; one of the major criterion is a score of four or more using the Beighton score with 
the other major criterion being arthralgia for longer than three months in four or more joints. Joint 
Hypermobility Syndrome is classified based on two major criteria or one major criterion and two minor 
criteria or four minor criteria being fulfilled. 
Up to 10% of a western population has GJH (18), with a declining prevalence with increasing age (19;20), 
a higher prevalence amongst women (20) and some ethnic groups (21). For example, the prevalence 
rises to 35% of males and 57% of females in a rural Nigerian population (22). With the JHS’ population, 
the   prevalence is estimated to be between 0.75% and 2% (23), but it has been reported to be as high as 
45% of all people referred to rheumatologists (24) and 30% of all people referred to a British 
musculoskeletal triage clinic (25). This can vary with ethnicity (26), for example 55% of Omani women 
presenting to a woman’s musculoskeletal physiotherapy service had JHS (27), and non-Caucasian 
women were diagnosed twice as frequently as Caucasian women in a UK general rheumatology clinic 
(24).  
Discussions regarding the classification of JHS is a timely issue. Scheper et al (2015) (28) have set out a 
number of challenges that relate to phenotyping JHS and its difference to GJH. The reported numbers of 
people with JHS in musculoskeletal services would suggest that recruitment to such studies should be 
straight forward. To assist our recruitment strategy we undertook a local survey to understand where 
people with JHS are referred within our secondary care setting. This was particularly relevant as our 
Consultant Rheumatologists’ impression was that the prevalence of JHS was lower than suggested in the 
literature within our general rheumatology clinics. Therefore, our aim was to establish the prevalence of 
JHS within the pain management, general rheumatology and an orthopaedic lower limb clinic, in order 
to target our recruitment to future trials effectively. 
Method 
A sample size of 101 people was calculated, based upon the assumption that the proportion of JHS 
within our clinics will be between 15% and 25% of the population. The first author, a senior 
physiotherapist with a special interest in JHS and experience of using the Brighton Criteria attended 
outpatient services run by the pain management, general rheumatology and orthopaedic lower limb 
clinics in one general hospital. The hospital is part of a group of hospitals in North West London, UK. 
Thirty clinics in total were attended between October 2013 and September 2015. As a normal part of 
the patients’ care the attendees were assessed for the presence of JHS using the Brighton Criteria noting 
the classification of the number of major and minor criteria. The percentage of attendees who had JHS 
was then recorded for each clinic.   
Results  
The results for 46  patients were sequentially recorded in each of the three clinics, thus a total of 138 
people were assessed. This represents a higher sample size than our sample size calculation suggested; 
this occurred as the count took place for all patients attending clinic on the surveyed days, which 
accounted for more people than required. 
The pain management and rheumatology clinics both demonstrated a similar prevalence for JHS; 39.1% 
and 37.0% respectively. The orthopaedics clinic demonstrated a much lower prevalence of 10.9%.  
The percentages have been further analysed by noting the Beighton score and noting whether the 
classification was based upon major or minor criteria (see Table 2). The percentage of people who were 
classified as having JHS with two major criteria in the pain management, rheumatology and orthopaedic 
clinics were 13.0%, 10.9% and 2.2% respectively. The percentage of people classified with a Beighton 
score of 4 or more and two minor criteria were 2.2%, 0% and 2.2%. The percentage of people classified 
with arthralgia for longer than 3 months in four or more joints and two minor criteria were 21.7%, 
23.9% and 4.3% respectively. Finally, the percentage of people classified with four minor criteria was 
2.2% in each group. 
  
Discussion 
More people with JHS presented to our pain management and general rheumatology clinics rather than 
the orthopaedic clinic. This reflects a more appropriate pathway for this multiple joint pathology, where 
orthopaedic surgery is rarely a chosen pathway of care.  
Although the presence of JHS was high in the pain management and rheumatology clinics, it is similar to 
the percentage that others have found (24;25). The presence of joint hypermobility measured as a 
Beighton score of 4 or more, is approximately what one might expect within the general population in 
the pain management and rheumatology clinics, but far lower than expected in the orthopaedic clinic. If 
GJH is approximately 10% of a Western population (18), why are these findings lower? The population 
demographic, particularly the ethnic origin, sex and age was not collected, but local area population 
statistics collected in 2014 (www.IBHF.gov.uk), demonstrated that the population considered 
themselves 78.1% white and 31.9% from other ethnic groups. The majority of the other ethnic groups 
are Black African (5.8%), Mixed (5.5%), other Asian (4%) and Black Caribbean (3.9%). This does not 
suggest that the percentage of GJH in the local population should be particularly low.  
The high percentage of people with JHS in two of the clinics is, in part, a reflection of classifying people 
who have a low Beighton score but have multiple joint pains from other sources. A low Beighton score 
may be a result of joints stiffening up with age. For example, people referred to the orthopaedic services 
may suffer with osteoarthritis and therefore represent a population with reduced range of motion. 
These figures may be an over classification from people who had co-morbidities that do not reflect a 
hypermobility syndrome. For example, joint pain and soft tissue lesions are commonly associated with 
some immunological conditions, which may present alongside unrelated varicose veins, a hernia or a 
prolapse that can occur in an older population. Indeed, the Brighton Criteria has been validated against 
a healthy population and not yet against  people with other musculoskeletal complaints (16).  That is, 
the Brighton Criteria only excludes a classification of JHS in the presence of Marfan or Ehlers-Danlos 
Syndrome (other than ED-HT) rather than following the exclusion of other disorders. Therefore, the 
sensitivity and specificity of the criteria requires further investigation. Remvig et al (2011) have 
suggested that further investigations should include the determination of features that may contribute 
towards heterogeneity of JHS (11). This stresses the need for the Brighton Criteria to be considered 
alongside a thorough history taking, consideration of other differential diagnoses and careful clinical 
reasoning to avoid the risk of over classification. For example, a shoulder dislocation that was traumatic 
in origin could commonly re-dislocate due to a Hill-Sachs lesion but fulfil a minor criterion. Careful 
history needs to be taken to avoid attributing such an unrelated dislocation to JHS. This may also be the 
case for myopia, a hernia from a traumatic football injury, or a prolapse sustained by a mother during 
traumatic childbirth delivery. Sub-classifications of JHS have been demonstrated in children(29) and 
adults (30). The identification of these subtypes were based on symptoms such as fatigue, 
gastrointestinal problems and postural orthostatic tachycardia syndrome. It should be noted that these 
features (fatigue (6;31), gastrointestinal problems (26) and postural orthostatic tachycardia syndrome 
(32)) although associated (2) are not, as yet, considered part of the classification criteria.  
In conclusion, recruitment to trials using the Brighton Criteria to achieve an accurate diagnosis of JHS 
from people with general hypermobility is challenging. Sensitivity and specificity testing of the Brighton 
Criteria against other populations is required, because this cohort of people who have widespread pain 
and symptoms requires accurate identification. This is important due to the significant affect it may 
have on their functional ability and quality of life and to ensure that they are directed to appropriate 
services.   
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Figure1: Bar chart showing the percentage of people classified with Joint Hypermobility Syndrome using 
the Brighton criteria in the three different clinics.   
 
 2 major Beighton + 2 minor Arthralgia + 2 minor 4 minor 
Pain management 13.0 2.2 21.7 2.2 
Rheumatology 10.9 0 23.9 2.2 
Orthopaedics 2.2 2.2 4.3 2.2 
 
Table 1. Demonstrates the percentage of people classified with the four different criteria in the pain 
management, general rheumatology and orthopaedic clinics. 
 
